What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?

Current Cardiology Reports

Volumn 13, Issue 6, 2011, Pages 492-501

  Khouri, Yazan ^a   Steigerwalt, Susan P ^a   Alsamara, Mershed ^a   McCullough, Peter A ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

Blood pressure targets; Cardiovascular events; Chronic kidney disease; Hypertension; Renal function; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; INDAPAMIDE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MONOTHERAPY; PROTEINURIA; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 81255157596     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0215-0     Document Type: Article

References (57)

1. PM Kearney M Whelton K Reynolds, et al. 2005 Global burden of hypertension: analysis of worldwide data Lancet 365 9455 217 223 15652604
2. PA Sarafidis S Li SC Chen AJ Collins, et al. 2008 Hypertension awareness, treatment, and control in chronic kidney disease Am J Med 121 4 332 340 18374693 10.1016/j.amjmed.2007.11.025
3. GL Bakris E Ritz 2009 The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented J Am Soc Hypertens 3 2 80 83 20409949 10.1016/j.jash.2009.02.001
4. S Nakai I Masakane T Akiba, et al. 2007 Overview of regular dialysis treatment in Japan (as of 31 December 2005) Ther Apher Dial 11 6 411 441 18028170 10.1111/j.1744-9987.2007.00523.x
5. United States Renal Data System. Annual Data Report, 2007. Available at: www.usrds.org.
6. GS Hill 2008 Hypertensive nephrosclerosis Curr Opin Nephrol Hypertens 17 3 266 270 18408477 10.1097/MNH.0b013e3282f88a1f
7. M Ruzicka KD Burns B Culleton, et al. 2007 Treatment of hypertension in patients with nondiabetic chronic kidney disease Can J Cardiol 23 7 595 601 17534470 10.1016/S0828-282X(07)70808-5 1:CAS:528:DC%2BD2sXnvFakt78%3D
8. K Rafiq H Hitomi D Nakano, et al. 2011 Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney J Pharmacol Sci 115 1 1 7 21186336 10.1254/jphs.10R07CR 1:CAS:528:DC%2BC3MXhsl2rt7s%3D
9. EL Penne J Neumann IH Klein, et al. 2009 Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment J Nephrol 22 2 208 215 19384838
10. B Williams NR Poulter MJ Brown, et al. 2004 Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV J Hum Hypertens 18 3 139 185 14973512 10.1038/sj.jhh. 1001683 1:STN:280:DC%2BD2c%2FotlGksg%3D%3D
11. S Lewington R Clarke N Qizilbash, et al. 2002 Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 9349 1903 1913 12493255 10.1016/S0140-6736(02)11911-8
12. Stamler J. Established major coronary risk factors. In: Marmot M, Elliot P, editors. Coronary heart disease epidemiology, from etiology to public health. New York: Oxford University Press; 1992. p. 55.
13. A Zanchetti L Hansson B Dahlöf, et al. 2001 Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group J Hypertens. 19 6 1149 1159 11403365 10.1097/00004872-200106000-00021 1:CAS:528:DC%2BD3MXktlSqsLY%3D
14. JS Jensen B Feldt-Rasmussen S Strandgaard, et al. 2000 Arterial hypertension, microalbuminuria, and risk of ischemic heart disease Hypertension 35 4 898 903 10775558 1:STN:280:DC%2BD3c3ktVejsA%3D%3D
15. R Lawrence 2011 Krakoff implementing home blood pressure into practice: what more do we need? Hypertension 57 1043 1044 10.1161/HYPERTENSIONAHA.110. 163493
16. JJ Sim SA Rasgon SF Derose, et al. 2007 Sleep apnea and hypertension: prevalence in chronic kidney disease J Clin Hypertens (Greenwich) 9 11 837 841 10.1111/j.1524-6175.2007.07176.x
17. JP Empana P Ducimetiere D Arveiler, et al. 2003 Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME study Eur Heart J 24 21 1903 1911 14585248 10.1016/j.ehj.2003.09.002 1:STN:280:DC%2BD3srgvFWitg%3D%3D
18. D Laurier PC Nguyen B Cazelles, et al. 1994 Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group J Clin Epidemiol 47 12 1353 64 7730844 10.1016/0895-4356(94)90079-5 1:STN:280:DyaK2M3kvVehuw%3D%3D
19. HW Hense H Schulte HH Löwel, et al. 2003 Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts Eur Heart J 24 10 937 945 12714025 10.1016/S0195-668X(03)00081-2
20. A Menotti PE Puddu M Lanti, et al. 2000 Comparison of the Framingham risk function-based coronary chart with a risk function from an Italian population study Eur Heart J 21 5 365 370 10666350 10.1053/euhj.1999.1864 1:STN:280:DC%2BD3c7jt12ltg%3D%3D
21. P Brindle J Emberson F Lampe, et al. 2003 Predictive accuracy of the Framingham coronary risk score in British men: prospective study BMJ 327 7426 1267 14644971 10.1136/bmj.327.7426.1267
22. K Fiscella P Franks 2004 Should years of schooling be used to guide treatment of coronary risk factors? Ann Fam Med 2 5 469 473 15506583 10.1370/afm.88
23. AV Chobanian GL Bakris HR Black, et al. 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 6 1206 1252 14656957 10.1161/01.HYP.0000107251. 49515.c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D
24. B Neal S MacMahon N Chapman, et al. 2000 Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 9246 1955 1964 11130523 10.1016/S0140-6736(00)03307-9 1:STN:280:DC%2BD3M%2FnvFaitA%3D%3D
25. RL Sacco PA Wolf WB Kannel, et al. 1982 Survival and recurrence following stroke: the Framingham Study Stroke 13 3 290 295 7080120 10.1161/01.STR.13.3. 290 1:STN:280:DyaL383gtVensQ%3D%3D
26. RL Sacco MA Foulkes JP Mohr, et al. 1989 Determinants of early recurrence of cerebral infarction: the Stroke Data Bank Stroke 20 8 983 989 2756550 10.1161/01.STR.20.8.983 1:STN:280:DyaL1Mzjt1Oksw%3D%3D
27. PROGRESS Collaborative Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 9287 1033 1041 10.1016/S0140-6736(01) 06178-5
28. P Verdecchia G Gentile F Angeli, et al. 2010 Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials J Hypertens 28 7 1356 1365 20375907 10.1097/HJH.0b013e328338e2bb 1:CAS:528: DC%2BC3cXnvFWksrg%3D Demonstrates not only BP reduction plays a key role in decreasing composite cardiovascular end points, but also the degree of that reduction has an effect
29. S Yusuf P Sleight J Pogue, et al. 2000 Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. Investigators New Engl J Med 342 3 145 153 10639539 10.1056/NEJM200001203420301 1:STN:280: DC%2BD3c%2Fpt1emug%3D%3D
30. P Svensson U de Faire P Sleight, et al. 2001 Comparative effect of ramipril on ambulatory and office blood pressure: a HOPE substudy Hypertension 38 6 E28 E32 11751742 10.1161/hy1101.099502 1:CAS:528:DC%2BD38XisVymsg%3D%3D
31. B Williams 2005 Recent hypertension trials: implications and controversies J Am Coll Cardiol 45 6 813 827 15766813 10.1016/j.jacc.2004.10.069
32. FH Messerli WB White JA Staessen, et al. 2002 If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials J Am Coll Cardiol 40 12 2201 2203 12505235 10.1016/S0735- 1097(02)02607-4
33. AM Thompson T Hu CL Eshelbrenner K Reynolds, et al. 2011 Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension JAMA 305 9 913 922 21364140 10.1001/jama.2011.250 1:CAS:528:DC%2BC3MXivVKgur0%3D
34. JB Lewis 2010 Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol 21 7 1086 1092 20576804 10.1681/ASN.2010030236
35. P Sleight J Redon P Verdecchia, et al. 2009 Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 27 7 1360 1369 19506526 10.1097/HJH.0b013e32832d7370 1:CAS:528:DC%2BD1MXnsVyis7g%3D Showed the J-type relationship between BP levels and cardiovascular events
36. L Hansson A Zanchetti SG Carruthers, et al. 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 9118 1755 1762 9635947 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D
37. ACCORD Study Group WC Cushman GW Evans RP Byington, et al. 2010 Effects of intensive blood-pressure control in type 2 diabetes mellitus New Engl J Med 362 17 1575 1585 20228401 10.1056/NEJMoa1001286 Found no extra benefits in risk reduction of cardiovascular events between the intensive and standard BP groups
38. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation published May 31, 2011. doi: 10.1161/CIRCULATIONAHA.110.016337.
39. GL Bakris 2011 Blood pressure targets in diabetes: is this the time for change?-CON (Rebuttal) J Clin Hypertens (Greenwich) 13 4 268 269 10.1111/j.1751-7176.2011.00441.x
40. S Bangalore J Qin S Sloan, et al. 2010 What is the optimal blood pressure in patients after acute coronary syndromes?: relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial Circulation 122 21 2142 2151 21060068 10.1161/CIRCULATIONAHA.109.905687 1:CAS:528:DC%2BC3cXhsV2gu73J Suggested that a target BP pressure below 110/70 mm Hg in patients hospitalized with ACS may lead to increased adverse events
41. FH Messerli G Mancia CR Conti 2006 Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144 12 884 893 16785477
42. MC Wang WC Tsai JY Chen, et al. 2005 Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease Am J Kidney Dis 45 3 494 501 15754271 10.1053/j.ajkd.2004.11.011
43. S Laurent P Boutouyrie R Asmar, et al. 2001 Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients Hypertension 37 5 1236 1241 11358934 1:STN:280:DC%2BD3M3ptVWrsw%3D%3D
44. P Boutouyrie AI Tropeano R Asmar, et al. 2002 Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study Hypertension 39 1 10 15 11799071 10.1161/hy0102.099031 1:CAS:528:DC%2BD38XpsF2gug%3D%3D
45. B Williams PS Lacy SM Thom, et al. 2006 Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 9 1213 1225 16476843 10.1161/CIRCULATIONAHA.105.595496 1:CAS:528:DC%2BD28XhvVektrg%3D
46. E Agabiti-Rosei G Mancia MF O'Rourke, et al. 2007 Central blood pressure measurements and antihypertensive therapy: a consensus document Hypertension 50 1 154 160 17562972 10.1161/HYPERTENSIONAHA.107.090068 1:CAS:528: DC%2BD2sXmtlKqsL0%3D
47. JM Lazarus JJ Bourgoignie VM Buckalew, et al. 1997 Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group Hypertension 29 2 641 650 9040451 1:STN:280:DyaK2s7pt1ymuw%3D%3D
48. K Norris J Bourgoigne J Gassman 2006 Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial Am J Kidney Dis 48 5 739 751 17059993 10.1053/j.ajkd.2006.08.004 1:CAS:528: DC%2BD28Xht12lsr3M
49. JT Wright Jr G Bakris T Greene, et al. 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2421 2431 12435255 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D
50. TH Jafar PC Stark CH Schmid, et al. 2003 Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 4 244 252 12965979 1:CAS:528:DC%2BD3sXnt12kurs%3D
51. CM O'Seaghdha V Perkovic TH Lam, et al. 2009 Blood pressure is a major risk factor for renal death: an analysis of 560,352 participants from Asian-Pacific region Hypertension 54 3 509 515 19597042 10.1161/HYPERTENSIONAHA. 108.128413 The lowest hazard ratio of renal death was associated with SBP/DBP of 120/70 mm Hg
52. DE Weiner H Tighiouart AS Levey, et al. 2007 Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease J Am Soc Nephrol 18 3 960 966 17301190 10.1681/ASN.2006080858
53. CP Kovesdy BK Trivedi K Kalantar-Zadeh, et al. 2006 Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease Nephrol Dial Transplant 21 5 1257 1262 16421161 10.1093/ndt/gfk057
54. P Ruggenenti A Perna G Gherardi, et al. 1999 Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 9176 359 364 10437863 10.1016/S0140-6736(98)10363-X 1:CAS:528:DyaK1MXlt1ajur8%3D
55. R Kunz C Friedrich M Wolbers, et al. 2008 Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 1 30 48 17984482
56. J Boggia Y Li L Thijs, et al. 2007 Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study Lancet 370 9594 1219 1229 17920917 10.1016/S0140-6736(07)61538-4
57. MA Weber S Julius SE Kjeldsen, et al. 2004 Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 363 9426 2049 2051 15207957 10.1016/S0140-6736(04)16456-8 1:CAS:528:DC%2BD2cXltVCitrg%3D